RecruitingNCT07478744
A single dose of SYT-510 for generalized anxiety
About this title
Read the official source — NCT07478744This study evaluates the safety and effectiveness of SYT-510 for people with anxiety.
Medication studyAges 18–55United Kingdom
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of SYT-510 for people with anxiety.
Who could participate?
Listed age limits: 18 years to 55 years.
What will I do during this study?
You receive one oral dose of SYT-510 or a matching placebo (an inactive comparison treatment) in the morning, depending on your group.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 22, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 24
- Sponsor
- Synendos Therapeutics AG
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07478744
- Official title
Show the full official title
A Study Investigating the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Single Dose of SYT-510 in Participants Who Meet DSM-5 Diagnostic Criteria for Generalized Anxiety Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
London
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of SYT-510 for people with anxiety.
Who is behind this study?
The study sponsor is Synendos Therapeutics AG.
Does this study involve medication?
Yes. The study involves medication, including SYT-510 and Placebo.
Who can participate?
Listed age limits: 18 years to 55 years.
Is this study still recruiting?
The registry lists this study as recruiting.
